Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has issued an update.
Shanghai Junshi Biosciences announced that its chairman, controlling shareholder and actual controller, Xiong Jun, has begun implementing a previously disclosed plan to increase his holdings in the company’s A and H shares by at least RMB100 million over a 12‑month period starting 12 April 2025, with at least RMB50 million to be allocated to A shares. As of this announcement, Xiong has purchased 100,000 A shares via centralized bidding on the Shanghai Stock Exchange for a total of RMB3.84 million, representing 0.01% of the company’s total share capital, and the increase plan remains in progress, signaling management’s confidence in the company while also being subject to execution risks stemming from capital market conditions and other unforeseen factors.
The most recent analyst rating on (HK:1877) stock is a Sell with a HK$21.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in both Shanghai and Hong Kong, focused on the research, development and commercialization of innovative therapies, with its share capital divided into A shares traded on the Shanghai Stock Exchange and H shares traded on the Hong Kong Stock Exchange.
Average Trading Volume: 3,545,970
Technical Sentiment Signal: Sell
Current Market Cap: HK$38.48B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.